Quisette P. Janssen

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

Quisette P. Janssen, Jacob L. van Dam, B. Bonsing et al. · BMC Cancer · 2021 · 170 citations · Full text

Medicine, Oncology, Surgery +16

Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment

Stijn van Roessel, Eran van Veldhuisen, Sjors Klompmaker et al. · JAMA Oncology · 2020 · 136 citations · Full text

Medicine, Oncology, Surgery +13

LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial

Bas Groot Koerkamp, Quisette P. Janssen, Jacob L. van Dam et al. · Annals of Oncology · 2023 · 58 citations · Full text

Medicine, Oncology, Surgery +15

Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades

Maren H. Harms, Quisette P. Janssen, René Adam et al. · Alimentary Pharmacology & Therapeutics · 2018 · 55 citations · Full text

Medicine, Internal Medicine, Disease Surveillance +11

FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium

Quisette P. Janssen, Jacob L. van Dam, Deesje Doppenberg et al. · JNCI Journal of the National Cancer Institute · 2022 · 54 citations · Full text

Medicine, Oncology, Surgery +14